Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INDP | US
0.28
17.83%
Healthcare
Biotechnology
30/06/2024
09/04/2026
1.85
1.59
1.85
1.51
Indaptus Therapeutics Inc. a clinical biotechnology company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma hepatocellular colorectal and pancreatic tumors as well as chronic hepatitis B virus and human immunodeficiency virus infection which is in Phase 2 clinical trial. The company was formerly known as Intec Parent Inc. and changed its name to Indaptus Therapeutics Inc. in August 2021. Indaptus Therapeutics Inc. is headquartered in New York New York.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
125.4%1 month
99.8%3 months
105.5%6 months
118.2%-
-
2.50
0.02
0.02
1.03
-
-
-16.48M
18.86M
18.86M
-
-
-
-
-127.04
1.54
0.45
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.50
Range1M
0.50
Range3M
2.15
Rel. volume
2.80
Price X volume
221.10K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 0.9496 | 20.33M | 1.77% | n/a | 2.92% |
| Lantern Pharma Inc. | LTRN | Biotechnology | 1.87 | 20.13M | -3.61% | n/a | 0.71% |
| iBio Inc | IBIO | Biotechnology | 2.2 | 20.10M | -1.79% | n/a | 20.92% |
| Edesa Biotech Inc | EDSA | Biotechnology | 5.92 | 19.22M | -0.67% | n/a | 1.35% |
| PLUR | PLUR | Biotechnology | 3.39 | 18.54M | 0.89% | n/a | 30845.83% |
| Enveric Biosciences Inc | ENVB | Biotechnology | 2.04 | 18.20M | 4.08% | n/a | 0.00% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.96 | 18.14M | 1.88% | n/a | 10.72% |
| DOMH | DOMH | Biotechnology | 2.88 | 18.08M | 0.00% | n/a | 7.66% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.93 | 17.86M | -4.87% | n/a | 0.00% |
| Cue Biopharma Inc | CUE | Biotechnology | 0.2929 | 17.63M | 6.98% | n/a | 52.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.16 | 16.95M | -4.13% | 0.03 | 16.03% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 11.02 | 16.78M | 94.36% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.651 | 12.58M | -0.82% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3 | 3.32M | 2.85% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2987 | 2.84M | 10.96% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.95 | 1.07M | -3.47% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.50 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 105.55 | - | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 18.86M | - | Emerging |